Valeant Pharmaceuticals Announces Canadian Approval Of Jublia
Valeant Pharmaceuticals International has received Health Canada regulatory approval for Jublia (efinaconazole 10% solution), a topical triazole antifungal agent developed for distal lateral subungual onychomycosis (DLSO). This is the first regulatory approval worldwide for Jublia.